Alzheimer’s Disease Against A Cancer – Part 1 of 3
Alzheimer’s Disease Against A Cancer. Although a scrutinize in 2012 suggested a cancer drug could reverse the thinking and memory problems associated with Alzheimer’s disease, three groups of researchers now break they have been unable to duplicate those findings. The teams said their research could have serious implications for patient safety since the drug involved in the study, bexarotene (Targretin), has sincere side effects, such as major blood-lipid abnormalities, pancreatitis, headaches, fatigue, weight gain, depression, nausea, vomiting, constipation and rash. “Anecdotally, we have all heard that physicians are treating their Alzheimer’s patients with bexarotene, a cancer treatment with severe side effects,” said study co-author Robert Vassar, a professor of cell and molecular biology at Northwestern University Feinberg School of Medicine, in Chicago.
This application should be ended immediately, given the failure of three independent research groups to replicate the plaque-lowering effects of bexarotene. The US Food and Drug Administration approved bexarotene in 1999 to care for refractory cutaneous T-cell lymphoma. Once approved, however, the drug also was available by prescription for “off-label” uses.